MNMD Stock Price, Mind Medicine Quote, Chart

Market Summary

USD8.23-0.42

Delayed

-4.86%

MNMD Stock Price

View Fullscreen

MNMD RSI Chart

MNMD Valuation

Market Cap

591.5M

Price/Earnings (Trailing)

-4.72

EV/EBITDA

-8.47

Price/Free Cashflow

-8.75

MarketCap/EBT

-12.25

MNMD Price/Earnings (Trailing)

MNMD Profitability

Return on Equity

-63.92%

Return on Assets

-45.48%

Free Cashflow Yield

-11.43%

MNMD Fundamentals

MNMD Earnings

Earnings (TTM)

-125.3M

Earnings Growth (Yr)

-119.22%

Earnings Growth (Qtr)

-127.96%

Breaking Down MNMD Revenue

Last 7 days

-11.1%

Last 30 days

-13.6%

Last 90 days

67.3%

Trailing 12 Months

161.3%

How does MNMD drawdown profile look like?

MNMD Financial Health

Current Ratio

3.91

MNMD Investor Care

Shares Dilution (1Y)

86.22%

Diluted EPS (TTM)

-2.94

Tracking the Latest Insider Buys and Sells of Mind Medicine

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	karlin dan	sold	-62,491	9.5	-6,578	chief medical officer
Mar 25, 2024	greenway schond l.	sold (taxes)	-54,376	9.78	-5,560	chief financial officer
Mar 25, 2024	barrow robert	sold	-156,930	9.5	-16,519	chief executive officer
Dec 26, 2023	barrow robert	sold	-48,050	3.63	-13,237	chief executive officer
Dec 26, 2023	karlin dan	sold	-24,589	3.63	-6,774	chief medical officer
Dec 26, 2023	greenway schond l.	sold	-20,516	3.63	-5,652	chief financial officer
Sep 25, 2023	karlin dan	sold	-24,729	3.57468	-6,918	chief medical officer
Sep 25, 2023	barrow robert	sold	-48,273	3.5761	-13,499	chief executive officer
Sep 25, 2023	greenway schond l.	sold	-20,608	3.57669	-5,762	chief financial officer
Aug 25, 2023	greenway schond l.	sold	-76,000	3.8	-20,000	chief financial officer

Which funds bought or sold MNMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	AWM Investment Company, Inc.	new	-	7,830,200	7,830,200	1.02%
May 16, 2024	JANE STREET GROUP, LLC	added	239	3,099,750	3,501,110	-%
May 16, 2024	Tidal Investments LLC	new	-	1,697,640	1,697,640	0.03%
May 15, 2024	MARSHALL WACE, LLP	new	-	18,786,300	18,786,300	0.03%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	2,200	3,400	3,459	-%
May 15, 2024	Royal Bank of Canada	added	654	361,000	381,000	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	new	-	2,820,000	2,820,000	0.29%
May 15, 2024	GREAT POINT PARTNERS LLC	new	-	18,800,000	18,800,000	2.93%
May 15, 2024	JANUS HENDERSON GROUP PLC	new	-	8,964,260	8,964,260	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	259	3,254,410	3,649,100	-%

Are Funds Buying or Selling MNMD?

Are funds buying MNMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MNMD

No. of Funds

Unveiling Mind Medicine's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 21, 2024	commodore capital lp	8.3%	5,833,333	SC 13G
Mar 15, 2024	deep track capital, lp	9.49%	6,666,667	SC 13G
Feb 14, 2023	cvi investments, inc.	4.9%	1,973,266	SC 13G/A
Oct 07, 2022	samberg joseph d	5.0%	1,915,000	SC 13G
Oct 06, 2022	cvi investments, inc.	5.6%	2e+06	SC 13G

Recent SEC filings of Mind Medicine

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 30, 2024	424B3	Prospectus Filed
Apr 30, 2024	424B3	Prospectus Filed
Apr 29, 2024	EFFECT	EFFECT
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 02, 2024	S-3	S-3
Apr 01, 2024	8-K	Current Report

Mind Medicine News

Latest updates

Mind Medicine Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	121.2%	276	125	142	142	156	170	181	134	149	164	82.00
Current Assets	145.9%	255	104	120	120	132	146	157	109	123	137	82.00
Cash Equivalents	153.1%	252	100	118	117	129	142	155	106	120	134	80.00
Goodwill	0%	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	-
Liabilities	71.3%	79.00	46.00	46.00	36.00	25.00	19.00	27.00	10.00	12.00	12.00	6.00
Current Liabilities	102.4%	65.00	32.00	31.00	35.00	24.00	18.00	26.00	8.00	11.00	10.00	3.00
Shareholder's Equity	150.9%	196	78.00	96.00	106	130	151	154	125	137	152	76.00
Retained Earnings	-18.7%	-344	-290	-266	-248	-219	-194	-189	-173	-156	-137	-44.64
Additional Paid-In Capital	46.7%	540	368	362	354	349	345	342	297	292	288	120
Shares Outstanding	73.1%	71.00	41.00	40.00	39.00	38.00	38.00	29.00	28.00	28.00	28.00	18.00
Float	-	-	-	-	140	-	-	-	272	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Cashflow From Operations	19.3%	-16,598	-20,563	-16,626	-13,845	-13,331	-12,849	-9,297	-15,127	-12,866	-7,833	-16,782	-11,171	-10,038	-	-
Share Based Compensation	-100.0%	-	3,676	4,226	3,842	3,750	1,376	4,286	4,253	3,792	4,344	4,105	32,988	1,279	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	113	-27.00	-67.00	-316	-	-
Cashflow From Financing	6427.1%	169,247	2,593	17,398	1,274	583	416	58,211	590	-166	127	820	7,889	89,988	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MNMD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 11,705	$ 12,599
General and administrative	10,499	8,263
Total operating expenses	22,204	20,862
Loss from operations	(22,204)	(20,862)
Other income/(expense):
Interest income	1,656	1,360
Interest expense	(434)	(76)
Foreign exchange loss, net	(525)	(52)
Change in fair value of 2022 USD Financing Warrants	(32,893)	(5,185)
Total other expense, net	(32,196)	(3,953)
Net loss	(54,400)	(24,815)
Other comprehensive loss
Gain on foreign currency translation	493	14
Comprehensive loss	$ (53,907)	$ (24,801)
Net loss per common share, basic	$ (1.14)	$ (0.65)
Net loss per common share, diluted	$ (1.14)	$ (0.65)
Weighted-average common shares, basic	47,860,757	38,077,251
Weighted-average common shares, diluted	47,860,757	38,077,251

MNMD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 252,332	$ 99,704
Prepaid and other current assets	3,139	4,168
Total current assets	255,471	103,872
Goodwill	19,918	19,918
Intangible assets, net		527
Other non-current assets	144	224
Total assets	275,533	124,541
Current liabilities:
Accounts payable	7,595	4,136
Accrued expenses	9,974	11,634
2022 USD Financing Warrants	47,700	16,476
Total current liabilities	65,269	32,246
Credit facility, long-term	14,190	14,129
Other liabilities, long-term	15	32
Total liabilities	79,474	46,407
Commitments and contingencies (Note 9)
Shareholders' Equity:
Common shares, no par value, unlimited authorized as of March 31, 2024 and December 31, 2023; 71,163,720 and 41,101,303 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	539,823	367,991
Accumulated other comprehensive income	836	343
Accumulated deficit	(344,600)	(290,200)
Total shareholders' equity	196,059	78,134
Total liabilities and shareholders' equity	$ 275,533	$ 124,541

About Mind Medicine

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ÃƒÅ¸4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

CEO	Mr. Robert Barrow
WEBSITE	mindmed.co
INDUSTRY	Biotechnology
EMPLOYEES	48

Mind Medicine Frequently Asked Questions

What is the ticker symbol for Mind Medicine? What does MNMD stand for in stocks?

MNMD is the stock ticker symbol of Mind Medicine. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mind Medicine (MNMD)?

As of Fri May 17 2024, market cap of Mind Medicine is 591.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNMD stock?

You can check MNMD's fair value in chart for subscribers.

What is the fair value of MNMD stock?

You can check MNMD's fair value in chart for subscribers. The fair value of Mind Medicine is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mind Medicine is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MNMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mind Medicine a good stock to buy?

The fair value guage provides a quick view whether MNMD is over valued or under valued. Whether Mind Medicine is cheap or expensive depends on the assumptions which impact Mind Medicine's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNMD.